Approximately 30% of prostatic adenocarcinoma (PCa) cases are attributed to hereditary causes. The National Comprehensive Cancer Network (NCCN) has published guidelines on genetic testing. The prevalence of the NCCN criteria for genetic testing in patients treated with surgery for high and intermediate risk PCa in not well characterized.
INTRODUCTION AND OBJECTIVES:
Approximately 30% of prostatic adenocarcinoma (PCa) cases are attributed to hereditary causes. The National Comprehensive Cancer Network (NCCN) has published guidelines on genetic testing. The prevalence of the NCCN criteria for genetic testing in patients treated with surgery for high and intermediate risk PCa in not well characterized.
METHODS: Patients with history of PCa treated with robotic surgery between January of 2016 and December of 2017 were identified from our well maintained intuitional database through an intuitional review board approved protocol. Only patients with available phone numbers and PCa Gleason score > 6 were included. A scripted phone call that operationalized NCCN criteria for testing into seven questions was used to contact patients. Prevalence of NCCN criteria in our patients 0 cohort was then quantified. Patient 0 s attitude towards tissue banking for study of genetic disease determinants was also examined.
RESULTS: Of the 450 patients identified as candidates for the study, 227 (50.4%) patients responded to the study team's phone calls. Average age of respondents was 64.6 years, 29.5% were African Americans, 21.3% had PCa > 7, 32.3% had positive family history for PCa, and 97.3% were health-insured. In individuals with family history of PCa, 28.8% had two family members affected, and 2.7% had three family members affected. Fathers were the most affected family members (55.7%), followed by brothers (22.7%). After scripted discussion with the patients, the prevalence of NCCN criteria for genetic testing was quantified and illustrated in table 1. During the same phone call, 31.5% of patients expressed agreement to have their samples acquired in the future into a tissue bank for research purposes into the genetic determinants of prostate cancer.
CONCLUSIONS: A recognizable percentage of post prostatectomy men with intermediate and high risk PCa fit the NCCN criteria for genetic testing, and genetic testing in this population is justified. Based on our data, there is a good interest among post prostatectomy men to contribute samples to research into inherited causes of prostate cancer.
Source of Funding: none

MP13-18 INCIDENTAL DETECTION AND TREATMENT OF PROSTATE CANCER AFTER HOLMIUM LASER ENUCLEATION OF THE PROSTATE: A LARGE COHORT ANALYSIS
Seth Teplitsky*, Joon Yau Leong, Tomy Perez, Patrick Shenot, Akhil Das, Philadelphia, PA INTRODUCTION AND OBJECTIVES: Holmium laser enucleation of the prostate (HoLEP) is a surgical treatment option for patients with benign prostatic hyperplasia (BPH). Here we identify the prevalence and treatment options for incidental prostate cancer (PCa) after HoLEP. We also aim to investigate the length of survival after PCa detection and treatment.
METHODS: A retrospective review, from an IRB approved database, of 515 patients that underwent a HoLEP by a single-surgeon at our institution between 2012 and 2017 was performed. All patients whose pathology report showed adenocarcinoma of the prostate were identified, and the chart was reviewed. Patients with a previously confirmed diagnosis of PCa were excluded from analysis.
RESULTS: Of 515 patients, 32 patients pathology showed PCa, of which 28 were incidental findings (5.44%). Of these, 13 patients (46.43%) had Gleason 3þ3 disease. Eight patients (28.57%) had Gleason 3þ4 or Gleason 4þ3 disease. The remaining seven patients (25.0%) had Gleason 4þ4 or higher. 20/28 (71.4%%) had urinary retention before surgery, while 7/7 (100%) with Gleason 4þ4 or higher had retention on presentation. Pathology reports showed that 16 (57.14%) of these 28 patient 0 s pathology showed cancer in less than 5% of the tissue, and 21/28 (75.0%) of patients had less than 25% of tissue affected. 14 of 28 (50.0%) opted for active surveillance (AS), 4 (14.29%) received radiation therapy plus hormonal treatment, 1 (3.57%) received exclusively hormonal therapy, and 1 (3.57%) received robotic prostatectomy. Of the AS group, one patient (7.14%) had disease progression and required hormonal therapy. Six (21.43%) patients were lost to follow up or followed up at an outside institution. Of the 28 patients, three are known to have died at a median of 24 months after cancer diagnosis.
CONCLUSIONS: Incidental findings of prostate cancer is not an uncommon phenomenon for those undergoing HoLEP for the relief of their BPH symptoms, and our results are consistent with previous findings. Of those identified, the most common finding is low-grade cancer for which active surveillance is a reasonable option, and will likely have a favorable outcome in their prostate cancer management. However, 25% of all cancers identified are aggressive and may present a challenge for management. All patients with Gleason 4þ4 or higher had urinary retention upon presentation, and therefore patients with this presentation may be considered for different counseling, including possible pre-HoLEP prostate biopsy for those with other risk factors.
Source of Funding: None
MP13-19 COMPARISON OF CANCER DETECTION RATES IN MICRO-ULTRASOUND BIOPSIES VERSUS ROBOTIC ULTRASOUND-MAGNETIC RESONANCE IMAGING FUSION BIOPSIES FOR PROSTATE CANCER
Oliver R. Claros*, Fabio Muttin, Rafael R. Tourinho-Barbosa, Anna C. Gallardo, Eric Barret, François Rozet, Nathalie Cathala, Dominique Prapotnich, Annick Mombet, Rafael Sanchez-Salas, Xavier Cathelineau, Paris, France INTRODUCTION AND OBJECTIVES: We aimed to compare the cancer detection rates in patients who underwent micro-ultrasound biopsy (MB) versus Robotic ultrasound-magnetic resonance imaging fusion biopsies (RFB) for prostate cancer.
METHODS: Between February 2017 and September 2018, 451 biopsies were performed at our institution. We performed a matched pair analysis based on prostate volume and PSA. We selected 271 patients that underwent target biopsy that composed the population of the study. In total 223 men underwent RFB, and 48 underwent MB. The
